BofA raised the firm’s price target on Bristol Myers (BMY) to $52 from $50 and keeps a Neutral rating on the shares. The firm’s 2026 revenues increase 1.5% and the EPS view is up 1% after the Q3 beat and raise report, noting that its long-term revenue and EPS estimates increase by low single digit percentages.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol-Myers Squibb Launches $7 Billion Tender Offer
- Bristol-Myers Squibb’s Earnings Call Highlights Growth and Challenges
- Bristol Myers files automatic mixed securities shelf
- Bristol-Myers Squibb: Balancing Strong Product Performance with Market Challenges and Patent Pressures
- Bristol Myers Squibb Reports Strong Q3 2025 Results